In a world first, Prof. Rasko and his team have completed the first human clinical trial using engineered stem cells to treat an immune disease called graft versus host disease. The work published today in Nature Medicine examines the use of human induced pluripotent stem cell-derived MSCs to treat 15 patients with steroid-resistant acute graft-versus-host disease, a condition affecting people who have received a bone marrow transplant.
“I’m proud of the achievement by all the international collaborators, patients and their families – along with the extraordinary team we have built here that allows us to undertake many research projects including basic translational and clinical.” says Prof. Rasko.
Read the article in The Sydney Morning Herald
Listen to the Interview on ABC Radio